Zynex Enters Chapter 11 with Lender Support as Shares Dive 30% and New CEO Appointed

Introduction

Zynex, Inc. (NASDAQ: ZYXI) is a Colorado-based medical device manufacturer specializing in non-invasive electrotherapy and patient monitoring solutions. Founded in 1996, the company develops and markets devices for pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. Its electrotherapy products, including TENS, IFC, and NMES systems, are FDA- and CE-cleared for home and clinical use.

Corporate Structure

Zynex operates through three subsidiaries:

• Zynex Medical, focusing on electrotherapy products for home use
• Zynex Monitoring Solutions, developing non-invasive cardiac monitoring devices for hospitals
• Zynex NeuroDiagnostics, producing electromyography (EMG) and autonomic nervous system diagnostic tools

As of December 2025, the company employs between 501 and 1,000 staff at its Englewood, Colorado headquarters. On LinkedIn, Zynex characterizes itself as a public company focused on improving patient quality of life. In December 2025, Zynex announced the appointment of Steven Dyson as Chief Executive Officer.

Electrotherapy by Natanael Melchor

Recent Developments and News

• On December 16, 2025, Zynex filed a Form 8-K with the Securities and Exchange Commission reporting items 1.01, 1.03, 2.04, 7.01, and 9.01.
• In December 2025, the company disclosed that it has voluntarily entered Chapter 11 court-supervised financial restructuring with financing from existing lenders, stating that operations and patient care remain uninterrupted.
• Earlier filings include a Form 10-Q for the quarter ended September 30, 2025 (filed November 17, 2025) and an 8-K covering executive and operational changes (filed November 17, 2025).

Financial and Strategic Analysis

As of December 17, 2025, Zynex shares closed at $0.2372, down 30.26% on the session, with trading volume of 1,365,884 shares. Key metrics (ttm):

• Market Capitalization: $20.1 million
• Enterprise Value: $78.6 million
• Price/Sales: 0.19 x
• Price/Book: 34.84 x
• Revenue: $108.2 million
• Net Loss: $73.96 million
• Profit Margin: –68.35%
• Return on Assets: –27.11%
• Cash on Hand: $13.26 million
• Levered Free Cash Flow: –$2.24 million

Analysts assign a Sell rating with a 12-month target price of $6.00, reflecting a high value subrating but low scores for management, safety, and financial strength. The Chapter 11 filing and CEO transition are part of Zynex’s strategy to stabilize liquidity, reduce leverage, and potentially grow in its core electrotherapy and monitoring markets.

Market Position and Industry Context

Zynex competes in the Medical Equipment Manufacturing industry, focusing on pain management and diagnostic monitoring. Regulatory and reimbursement pressures impact device adoption, while larger competitors have greater R&D budgets and broader sales channels. With a medium industry subrating and a focused product portfolio, Zynex seeks to leverage its restructuring to support existing devices and develop new offerings. Trading at a discount to sales but with a high price/book multiple, the company faces execution risk amidst its specialized market position.

TL;DR

• Entered Chapter 11 restructuring in December 2025 under court supervision with lender financing
• Appointed Steven Dyson as CEO to guide reorganization and future strategy
• Shares fell 30.26% on December 17, 2025, to $0.2372, closing below the 52-week low of $0.38
• Analysts maintain a Sell rating and $6 target, highlighting valuation disparity and reliance on successful restructuring